CN1526818A - 一种阻断乙肝病毒表达的方法 - Google Patents
一种阻断乙肝病毒表达的方法 Download PDFInfo
- Publication number
- CN1526818A CN1526818A CNA03119222XA CN03119222A CN1526818A CN 1526818 A CN1526818 A CN 1526818A CN A03119222X A CNA03119222X A CN A03119222XA CN 03119222 A CN03119222 A CN 03119222A CN 1526818 A CN1526818 A CN 1526818A
- Authority
- CN
- China
- Prior art keywords
- sidna
- seq
- hepatitis
- plasmid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000000903 blocking effect Effects 0.000 title abstract 3
- 239000013612 plasmid Substances 0.000 claims abstract description 35
- 210000005229 liver cell Anatomy 0.000 claims abstract description 14
- 108091027548 SiDNA Proteins 0.000 claims abstract 11
- 108091030071 RNAI Proteins 0.000 claims abstract 7
- 230000009368 gene silencing by RNA Effects 0.000 claims abstract 7
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 238000013461 design Methods 0.000 claims description 10
- 108091008146 restriction endonucleases Proteins 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims 4
- 238000005516 engineering process Methods 0.000 abstract description 12
- 208000002672 hepatitis B Diseases 0.000 abstract description 4
- 238000010276 construction Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 35
- 239000005090 green fluorescent protein Substances 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 24
- 238000001890 transfection Methods 0.000 description 21
- 230000000692 anti-sense effect Effects 0.000 description 20
- 239000000427 antigen Substances 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 12
- 108020004459 Small interfering RNA Proteins 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101710142246 External core antigen Proteins 0.000 description 2
- 241000723754 Flock house virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101150003160 X gene Proteins 0.000 description 1
- 101710086987 X protein Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000001553 hepatotropic effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
基因 | 功能 | |
Pre-Surface1 | 编码表面抗原HBsAg,诊断主要指标 | |
Pre-Surface2 | ||
Surface | ||
Pre-Core | 编码e抗原(HBeAg)血清指标 | |
Core | 编码核心抗原(HBcAg),核结构蛋白 | |
P-基因 | 编码DNA聚合酶/反转录酶,病毒复制 | |
X-基因 | 编码x抗原(HBxAg),功能未定 |
Sequence NO. | GenBank NO. |
Sequence 1 | AB076679 |
Sequence 2 | AB076678 |
Sequence 3 | AY090461 |
Sequence 4 | AY090460 |
Sequence 5 | AY090459 |
Sequence 6 | AY090458 |
Sequence 7 | AY090457 |
Sequence 8 | AY090456 |
Sequence 9 | AY090455 |
Sequence 10 | AY090454 |
Sequence 11 | AY090453 |
Sequence 12 | AY090452 |
Sequence 13 | E10905 |
Sequence 14 | NC_003977 |
Sequence 15 | AB074756 |
Sequence 16 | AB074755 |
Sequence 17 | AB064316 |
Sequence 18 | AB064315 |
Sequence 19 | AB064314 |
用于设计siDNA的HBV序列保守区 | nt | 序列所在的蛋白编码区* | |
1 | (404)TTC CTC TTC ATC CTG CTG CTA TGC CTC ATC TTC TT* | 35 | P-1 and HBsAg |
2 | (640)CCT ATG GGA GTG GGC CTC AG | 20 | P-1 and HBsAg |
3 | (1866)TTC AAG CCT CCA AGC TGT GCC TTG G | 25 | HBeAgCore |
4 | (2373)GAA GAA GAA CTC CCT CGC CTC GCA GAC G | 28 | HBeAgCore和P-2 |
pBS/U6 | siDNA-1 | siDNA-2 | siDNA-3 | siDNA-4 | |
抑制率(%) | 0 | 80±8.8 | 21.9±1.1 | 60* | 39.0±0.041 |
Claims (11)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB03119222XA CN1257284C (zh) | 2003-03-05 | 2003-03-05 | 一种体外阻断乙肝病毒表达的方法 |
AU2003258452A AU2003258452A1 (en) | 2003-03-05 | 2003-08-25 | Rna interference based methods and compositions for inhibiting hbv gene expression |
PCT/CN2003/000718 WO2004078181A1 (en) | 2003-03-05 | 2003-08-25 | Rna interference based methods and compositions for inhibiting hbv gene expression |
KR1020057016557A KR20060029597A (ko) | 2003-03-05 | 2003-08-25 | Rna 간섭에 기반한 hbv 유전자 발현의 억제 방법 및조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB03119222XA CN1257284C (zh) | 2003-03-05 | 2003-03-05 | 一种体外阻断乙肝病毒表达的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1526818A true CN1526818A (zh) | 2004-09-08 |
CN1257284C CN1257284C (zh) | 2006-05-24 |
Family
ID=32932360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB03119222XA Expired - Fee Related CN1257284C (zh) | 2003-03-05 | 2003-03-05 | 一种体外阻断乙肝病毒表达的方法 |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR20060029597A (zh) |
CN (1) | CN1257284C (zh) |
AU (1) | AU2003258452A1 (zh) |
WO (1) | WO2004078181A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1312283C (zh) * | 2004-12-07 | 2007-04-25 | 浙江大学 | 乙肝病毒基因的小干扰核糖核酸序列及制备方法 |
CN101979554A (zh) * | 2010-10-28 | 2011-02-23 | 百奥迈科生物技术有限公司 | 一种干扰HBV基因的siRNA分子及其应用 |
CN101979553A (zh) * | 2010-10-28 | 2011-02-23 | 百奥迈科生物技术有限公司 | 一种干扰HBV基因的siRNA分子及其抗病毒应用 |
CN102021170A (zh) * | 2010-10-28 | 2011-04-20 | 百奥迈科生物技术有限公司 | 一种干扰乙型肝炎病毒基因的siRNA分子及其应用 |
CN102762215A (zh) * | 2009-10-16 | 2012-10-31 | 葛兰素集团有限公司 | Hbv反义抑制剂 |
CN106191060A (zh) * | 2011-04-21 | 2016-12-07 | Isis制药公司 | 乙型肝炎病毒(hbv)表达的调节 |
CN111372593A (zh) * | 2017-10-20 | 2020-07-03 | 戴瑟纳制药公司 | 治疗乙型肝炎感染的方法 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
SG173218A1 (en) | 2003-06-12 | 2011-08-29 | Alnylam Pharmaceuticals Inc | Conserved hbv and hcv sequences useful for gene silencing |
ATE555202T1 (de) | 2004-08-16 | 2012-05-15 | Immune Disease Inst Inc | Verfahren zur lieferung von rna-interferenz und verwendungen damit |
JP2008525029A (ja) * | 2004-12-22 | 2008-07-17 | ニュークレオニクス・インコーポレイテッド | 遺伝子サイレンシングに有用なhbvおよびhcv保存配列 |
KR20100060018A (ko) * | 2005-03-09 | 2010-06-04 | 재단법인 목암생명공학연구소 | 작은 간섭 rna 및 이를 포함하는 b형 간염 바이러스 치료용 약학 조성물 |
CN100420749C (zh) * | 2006-02-10 | 2008-09-24 | 南京吉脉生物技术有限公司 | 针对HBV基因的ShRNA在制备抑制乙肝病毒复制药物中的应用 |
GB2439543A (en) * | 2006-06-27 | 2008-01-02 | Viruvation B V | Polyoma viral vector production cell lines and nucleic acids expressing dsRNA viral sequences |
WO2010012244A1 (zh) * | 2008-08-01 | 2010-02-04 | 苏州瑞博生物技术有限公司 | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 |
WO2012045894A1 (es) * | 2010-10-05 | 2012-04-12 | Proyecto De Biomedicina Cima, S.L. | Compuestos y composiciones para el tratamiento de enfermedades debidas a la infección por el virus de la hepatitis b |
CN101979558B (zh) * | 2010-10-28 | 2015-09-02 | 百奥迈科生物技术有限公司 | 一种靶向乙型肝炎病毒基因的siRNA分子及其应用 |
CN101979556B (zh) * | 2010-10-28 | 2015-01-21 | 百奥迈科生物技术有限公司 | 一种siRNA靶向分子及其应用 |
WO2012075337A2 (en) | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
EP2966170A1 (en) * | 2014-07-10 | 2016-01-13 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | HBV inactivation |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
EP3395363B1 (en) * | 2015-11-09 | 2022-10-19 | Purotech Bio, Inc. | Compounds for use in treating hbv-and hcv-related conditions |
KR102358280B1 (ko) * | 2016-05-05 | 2022-02-07 | 베니텍 바이오파마 리미티드 | B형 간염 바이러스(hbv) 감염 처리용 시약 및 그 용도 |
KR101879329B1 (ko) | 2016-06-13 | 2018-07-17 | 충북대학교 산학협력단 | 유전자 차별 발현 분석을 위한 RNA-seq 발현량 데이터 시뮬레이션 방법 및 이를 기록한 기록매체 |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
EP3718572B1 (en) * | 2017-12-01 | 2024-07-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use |
JP2021504415A (ja) | 2017-12-01 | 2021-02-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. | 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用 |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
KR20210043647A (ko) | 2018-08-13 | 2021-04-21 | 알닐람 파마슈티칼스 인코포레이티드 | B형 간염 바이러스 (HBV) dsRNA 제제 조성물 및 이의 사용 방법 |
WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU662304B2 (en) * | 1990-10-22 | 1995-08-31 | Fox Chase Cancer Center | DNA construct for providing RNA therapy |
CN1215058A (zh) * | 1997-10-21 | 1999-04-28 | 中国科学院上海生物化学研究所 | 新的三链形成寡核苷酸结构及其在抗乙肝病毒中的应用 |
EP1384784A1 (en) * | 2001-03-30 | 2004-01-28 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Method for reversible inhibition of gene expression by modified ribonucleoproteins |
-
2003
- 2003-03-05 CN CNB03119222XA patent/CN1257284C/zh not_active Expired - Fee Related
- 2003-08-25 WO PCT/CN2003/000718 patent/WO2004078181A1/en not_active Application Discontinuation
- 2003-08-25 AU AU2003258452A patent/AU2003258452A1/en not_active Abandoned
- 2003-08-25 KR KR1020057016557A patent/KR20060029597A/ko not_active Application Discontinuation
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1312283C (zh) * | 2004-12-07 | 2007-04-25 | 浙江大学 | 乙肝病毒基因的小干扰核糖核酸序列及制备方法 |
CN102762215A (zh) * | 2009-10-16 | 2012-10-31 | 葛兰素集团有限公司 | Hbv反义抑制剂 |
CN101979554A (zh) * | 2010-10-28 | 2011-02-23 | 百奥迈科生物技术有限公司 | 一种干扰HBV基因的siRNA分子及其应用 |
CN101979553A (zh) * | 2010-10-28 | 2011-02-23 | 百奥迈科生物技术有限公司 | 一种干扰HBV基因的siRNA分子及其抗病毒应用 |
CN102021170A (zh) * | 2010-10-28 | 2011-04-20 | 百奥迈科生物技术有限公司 | 一种干扰乙型肝炎病毒基因的siRNA分子及其应用 |
CN101979553B (zh) * | 2010-10-28 | 2015-07-01 | 百奥迈科生物技术有限公司 | 一种干扰HBV基因的siRNA分子及其抗病毒应用 |
CN102021170B (zh) * | 2010-10-28 | 2015-07-01 | 百奥迈科生物技术有限公司 | 一种干扰乙型肝炎病毒基因的siRNA分子及其应用 |
CN101979554B (zh) * | 2010-10-28 | 2015-08-26 | 百奥迈科生物技术有限公司 | 一种干扰HBV基因的siRNA分子及其应用 |
CN106191060A (zh) * | 2011-04-21 | 2016-12-07 | Isis制药公司 | 乙型肝炎病毒(hbv)表达的调节 |
CN111372593A (zh) * | 2017-10-20 | 2020-07-03 | 戴瑟纳制药公司 | 治疗乙型肝炎感染的方法 |
CN111372593B (zh) * | 2017-10-20 | 2024-03-19 | 戴瑟纳制药公司 | 治疗乙型肝炎感染的方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2003258452A8 (en) | 2004-09-28 |
WO2004078181A1 (en) | 2004-09-16 |
CN1257284C (zh) | 2006-05-24 |
KR20060029597A (ko) | 2006-04-06 |
AU2003258452A1 (en) | 2004-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1257284C (zh) | 一种体外阻断乙肝病毒表达的方法 | |
CN1458973A (zh) | 前脂肪细胞系 | |
CN101054577A (zh) | 抑制Bax基因表达的siRNA和表达载体及其作为乙型病毒性肝炎治疗药物的应用 | |
CN1800388A (zh) | 八种人源miRNA | |
CN101054591A (zh) | 靶向激活慢性粒细胞白血病蛋白激酶pkr的寡核苷酸及其应用 | |
CN1908187A (zh) | 蛋白质精氨酸甲基转移酶5在白血病细胞检测和治疗中的应用 | |
CN1840709A (zh) | 筛选与鉴定治疗免疫耐受相关疾病功能基因serpinh1的方法 | |
CN1654074A (zh) | 抗肝癌基因药物组合物、小分子干扰rna及其筛选方法 | |
CN1244375C (zh) | 人肝再生相关蛋白及其应用 | |
CN1300315C (zh) | 奶牛之犊牛前胸腺素基因及其克隆方法与应用 | |
CN1233831C (zh) | 抑制人bc1-2基因表达的siRNA和表达质粒及其在制药中的应用 | |
CN1948484A (zh) | 抑制人hPEBP4基因表达的siRNA及其应用 | |
CN1884496A (zh) | 逆转录病毒包装细胞系和肝细胞靶向性导入方法 | |
CN1162547C (zh) | 靶向肝癌的乙肝病毒反义rna表达载体及其构建方法与用途 | |
CN1840707A (zh) | 基于免疫耐受树突细胞筛选免疫耐受相关疾病的基因rgs1的方法 | |
CN1587406A (zh) | 抑制bc1-2基因表达的siRNA双链及其应用 | |
CN1231587C (zh) | 甜菜黑色焦枯病毒作为外源基因的表达载体 | |
CN1272435C (zh) | 日本血吸虫中国大陆株SjPP基因及其克隆、表达和应用 | |
CN1740315A (zh) | 一种转基因小鼠肝病动物模型、其制备方法及应用 | |
CN1727477A (zh) | 抑制肿瘤和白血病细胞VEGF表达和增殖的siRNA及应用 | |
CN1135262C (zh) | 一种高效增殖丙肝病毒体的方法及该方法所用的载体 | |
CN1305898C (zh) | 丙型肝炎病毒被膜蛋白hvr1模拟多肽、其编码基因及用途 | |
CN1580070A (zh) | 一组抗hbv感染及防治乙型肝炎的核苷酸序列及其应用 | |
CN1648249A (zh) | 抑制sars病毒基因表达的小分子干扰核糖核酸 | |
CN1714870A (zh) | 人同源盒基因lhx4在制备嗜铬细胞瘤治疗药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: BOAO BIOLOGICAL CO., LTD.; QINGHUA UNIVERSITY Free format text: FORMER NAME OR ADDRESS: CAPITALBIO CORPORATION; QINGHUA UNIVERSITY |
|
CP03 | Change of name, title or address |
Address after: 102206 No. 18, life science Road, Beijing, Changping District Co-patentee after: Tsinghua University Patentee after: Capitalbio Corporation Address before: 100084, No. 2, Qinghua West Road, Beijing, Haidian District Co-patentee before: Tsinghua University Patentee before: Boao Biochip Co., Ltd., Beijing |
|
C56 | Change in the name or address of the patentee |
Owner name: CAPITALBIO CORPORATION CO., LTD. Free format text: FORMER NAME: CAPITALBIO CORPORATION |
|
CP01 | Change in the name or title of a patent holder |
Address after: 102206 Beijing City, Changping District Life Science Park Road No. 18 Patentee after: CAPITALBIO CORPORATION Patentee after: Tsinghua University Address before: 102206 Beijing City, Changping District Life Science Park Road No. 18 Patentee before: Capitalbio Corporation Patentee before: Tsinghua University |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060524 Termination date: 20210305 |
|
CF01 | Termination of patent right due to non-payment of annual fee |